Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study


YASİN A. İ. , Aydin S. G. , SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli Ç., ...More

Future Oncology, vol.18, no.10, pp.1235-1244, 2022 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 10
  • Publication Date: 2022
  • Doi Number: 10.2217/fon-2021-1248
  • Title of Journal : Future Oncology
  • Page Numbers: pp.1235-1244
  • Keywords: cancer, chemotherapy, CoronaVac, COVID-19, COVID-19 vaccines, immunotherapy, malignancy, SARS-CoV-2

Abstract

© 2022 Future Medicine Ltd.Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov.